Background
Secondary injury mechanisms, especially neuroinflammation, heavily influence neurological outcomes after initial trauma. The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway has recently been identified. It mediates innate immune activation following brain injury. This pathway's activation promotes microglial activation. It also triggers the release of pro-inflammatory cytokines. This contributes to neuronal damage and impairs recovery. Therefore, pharmacological inhibition of the cGAS-STING signaling pathway is a promising neuroprotective strategy. However, existing preclinical evidence has not yet been systematically synthesized.
Wellness insights
Social support networks of older adults before, during and after the COVID-19 pandemic
College Mental Health Crisis Shows Signs of Easing
Why Depression Subtypes Matter: 25 Years of Clinical Lessons
Choosing Adjunctive Therapy for Major Depressive Disorder: A Focus on Non-NegotiablesMethods
A systematic literature search was conducted. Databases included MEDLINE, EMBASE, and Web of Science. No language or publication date restrictions were applied. Two reviewers independently screened titles and abstracts. Full-text eligibility was then assessed independently. Two reviewers will also independently extract data. Eligible studies will involve in vivo animal models of TBI. These studies must investigate direct or indirect pharmacological inhibition of the cGAS-STING pathway. Treatment must be administered after injury. Comparisons will be made against vehicle-treated or untreated controls.
Outcomes
The primary outcome will be quantitative measures of microglial activation. This will be assessed within 72 hours post-injury. Preferred measures include Iba1-positive cell density. Percentage of area occupied by Iba1-positive cells is also preferred. Secondary outcomes include astrocytic reactivity. Cytokine expression (TNF-α, IL-1β, IL-6) will be measured. Lesion volume and neurological functional recovery are also secondary outcomes.
Risk of Bias and Statistical Analysis
The SYRCLE tool will be used to assess the risk of bias. Where appropriate, pooled effect sizes will be calculated using random-effects meta-analysis. Heterogeneity, publication bias, and certainty of evidence will also be evaluated.
Significance
This systematic review and meta-analysis will clarify the magnitude and consistency of therapeutic effects. It will inform the translational potential of this strategy. Methodological limitations will be identified. This will guide future experimental and clinical research.
Data Availability
No datasets have been generated or analyzed at the protocol stage. Upon completion of the systematic review and meta-analysis, extracted datasets will be provided. Risk of bias assessments will be included. Methodological quality assessments will also be provided. Complete electronic search strategies will be supplied as supplementary data. These will be publicly accessible. The statistical analysis code used for meta-analysis reproduction will be deposited in a public repository.
Funding and Competing Interests
No specific funding was received for this work. No authors have competing interests.
Abbreviations
ARRIVE: Animal Research: Reporting of In Vivo Experiments; CAMARADES: Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies; CI: confidence interval; cGAS: cyclic GMP-AMP synthase; cGAS-STING: cyclic GMP-AMP synthase-stimulator of interferon genes; DNA: deoxyribonucleic acid; DOI: digital object identifier; ELISA: enzyme-linked immunosorbent assay; GFAP: glial fibrillary acidic protein; GRADE: Grading of Recommendations Assessment, Development and Evaluation; I2: I-squared; TBI: traumatic brain injury.